Drug Approval | November 10, 2024
Granules India’s Unit V facility secures USFDA EIR with NAI status
The FDA conducted a comprehensive Pre-Approval Inspection (PAI) and cGMP audit
The FDA conducted a comprehensive Pre-Approval Inspection (PAI) and cGMP audit
Revenue share from the North America increased to 79% in Q2 FY25 as compared to 67% in Q2 FY24
Granules now has a total of 67 ANDA approvals from the USFDA
Glycopyrrolate Oral Solution is an anticholinergic medication indicated for pediatric patients
Trazodone tablets are indicated for the treatment of major depressive disorder in adults
Granules India has reported total income of Rs. 1181.92 crores during the period ended June 30, 2024
Finance Minister Nirmala Sitharaman is set to present the full budget for the current financial year on July 23
_256_384.jpg)
This facility manufactures APIs & formulations of oncology and non-oncology products.
Granules India has reported total income of Rs. 1156.23 crores during the period ended December 31, 2023
Sales in the US region grew well, partially offset by the decline in the LATAM and European regions
Subscribe To Our Newsletter & Stay Updated
